Sucampo Pharmaceuticals (SCMP) 21.75 $SCMP Sucampo

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 7:45 PM

Sucampo Pharmaceuticals (SCMP) 21.75 $SCMP

Sucampo Announces First Quarter 2015 Earnings Call
GlobeNewswire - Wed Apr 22, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will host its first quarter 2015 financial results teleconference and webcast at 8:30 a.m. Eastern on Wednesday, May 6, 2015. The press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets that day.
SCMP: 21.75 (+0.47)

Roche's Avastin's Label Expanded in EU for Cervical Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 12:00PM CDT
Roche Holding AG (RHHBY) received positive news when the European Commission approved yet another label expansion of its oncology drug Avastin.
ACT: 295.22 (+0.69), VRX: 206.93 (-3.92), SCMP: 21.75 (+0.47)

Can The Uptrend Continue for Sucampo Pharmaceuticals (SCMP)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 8:05AM CDT
Can The Uptrend Continue for Sucampo Pharmaceuticals (SCMP)?
SCMP: 21.75 (+0.47)

Nasdaq stocks posting largest percentage increases
AP - Wed Apr 08, 1:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
APTO: 5.94 (-0.53), SINA: 37.19 (+0.98), ADXS: 22.18 (+0.10), AGRX: 12.25 (+0.17), CLVS: 85.04 (-1.36), HOFT: 24.00 (unch), ASPS: 18.07 (+1.32), CTSO: 7.13 (-0.06), SCMP: 21.75 (+0.47), HOLI: 23.74 (+0.58), BIND: 7.01 (-0.30), APS.TO: 7.25 (-0.65)

Sucampo Announces Webcast of Its Presentation at the 14th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 07, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 14 Annual Needham Healthcare Conference taking place April 14, 2015 at 1:40 PM ET.
SCMP: 21.75 (+0.47)

Sucampo Pharmaceuticals
at Investor's Business Daily - Mon Apr 06, 5:41PM CDT
Sucampo Pharmaceuticals (SCMP) was initiated with a buy rating by Guggenheim. Analysts said that the biotech's pipeline and M&A could add upside to lead drug Amitiza. Shares rose 9.8% to 17.21.
SCMP: 21.75 (+0.47)

Stocks Add To Gains; Sucampo Up On New Rating
at Investor's Business Daily - Mon Apr 06, 12:25PM CDT
Stocks continued to inch higher Monday afternoon after staging a big upside reversal earlier. The S&P 500 rallied 0.9%, thanks to energy and mining stocks. The benchmark index had been off 0.5% near the open. The Nasdaq rose 0.7% and the Dow Jones...
NOW: 77.72 (+0.22), ALTR: 42.78 (-0.46), SCMP: 21.75 (+0.47), INTC: 32.70 (+0.27), EPAM: 67.99 (-0.16)

Insider Trading Alert - SCMP, SE And CNC Traded By Insiders
at The Street - Mon Apr 06, 12:00PM CDT
Stocks with insider trader activity include SCMP, SE and CNC
CNC: 70.90 (+0.12), SE: 37.82 (+0.26), SCMP: 21.75 (+0.47)

Sucampo Stock Spikes On Bullish Initiation Report
at Investor's Business Daily - Mon Apr 06, 11:57AM CDT
Hot biotech Sucampo Pharmaceuticals (SCMP) rose more than 10% in early trading Monday after Guggenheim launched coverage with a buy rating, seeing multiple growth drivers ahead. Analyst Louise Chen wrote that Sucampo's constipation drug Amitiza still...
ACT: 295.22 (+0.69), IRWD: 15.07 (-0.19), SCMP: 21.75 (+0.47)

InsiderInsights.com Daily Round Up 4/2/15: AGCO, BH, RWC, VNCE
InsiderInsights - at Seeking Alpha - Fri Apr 03, 7:27AM CDT

LBTYK: 49.03 (-0.11), OLED: 46.98 (-0.58), GMAN: 8.63 (-0.17), UNF: 119.62 (-1.07), AGCO: 48.16 (-0.16), LNG: 78.61 (+1.61), VNCE: 19.10 (-0.08), LM: 54.46 (+0.67), SNFCA: 5.40 (+0.06), K: 63.98 (+0.12), BH: 396.99 (-5.47), RCAP: 8.49 (-0.08), SCMP: 21.75 (+0.47), RWC: 6.24 (+0.12), COST: 146.98 (-0.36), SIX: 49.97 (+1.37), DAVE: 29.37 (+0.05)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 11:49AM CDT

TRVN: 6.91 (-0.53), WGO: 20.92 (-0.21), CCSC: 5.36 (-0.04), OTIV: 1.58 (+0.03), DPLO: 34.52 (+0.26), CNAT: 6.31 (-0.15), WGBS: 4.66 (-0.08), HKTV: 7.67 (-0.33), DVD: 2.34 (-0.02), SEDG: 23.81 (+0.13), ENVA: 19.54 (+0.31), SEED: 1.66 (+0.05), RHT: 75.76 (+0.54), SCMP: 21.75 (+0.47), SGNT: 25.43 (-0.29), WRLD: 74.99 (+0.21), VBLT: 4.37 (-0.08), RCON: 1.87 (-0.04), SNDK: 68.48 (+0.56)

Stocks Off Morning Lows; Red Hat Up On Earnings
at Investor's Business Daily - Thu Mar 26, 11:10AM CDT
Stocks were off their session lows but still in the red near Thursday's midpoint amid conflict in the Middle East. The Nasdaq pared a 1% loss to 0.3%. The S&P 500 cut a 0.8% deficit to 0.1%. The Dow Jones industrial average was also off 0.1%. Volume...
FRSH: 16.76 (-0.31), RHT: 75.76 (+0.54), SCMP: 21.75 (+0.47), FRGI: 59.39 (-0.22)

Sucampo prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 8:26AM CDT

SCMP: 21.75 (+0.47)

Sucampo Prices Public Offering of Common Stock by Selling Stockholders
GlobeNewswire - Thu Mar 26, 8:19AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the pricing of an underwritten public offering of 4,000,000 shares of its class A common stock by selling stockholders, offered at a price to the public of $14.00 per share for an aggregate offering of $56.0 million of class A common stock. All shares will be offered by S&R Technology Holdings, LLC, S&R Foundation, Dr. Sachiko Kuno and Dr. Ryuji Ueno. Sucampo will not sell any shares or receive any proceeds from the offering. The underwriters have been granted a 30-day option to purchase up to an aggregate of 600,000 additional shares of class A common stock. The offering is expected to close on or about March 31, 2015, subject to customary closing conditions.
SCMP: 21.75 (+0.47)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 8:13AM CDT

EXXI: 3.87 (-0.13), OTIV: 1.58 (+0.03), CNAT: 6.31 (-0.15), EXAS: 22.28 (+0.24), WGBS: 4.66 (-0.08), FIVE: 35.27 (-0.01), ROSG: 3.83 (-0.20), NVAX: 8.51 (+0.09), RHT: 75.76 (+0.54), SCMP: 21.75 (+0.47), CLLS: 31.30 (-0.91), MAGS: 4.95 (-0.02), VBLT: 4.37 (-0.08), SNDK: 68.48 (+0.56)

Sucampo off 14% premarket on pending stock sales by shareholders
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 7:58AM CDT

SCMP: 21.75 (+0.47)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PathoSearch: A New Era in Pathology With Visual Search

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Countries Eye New Investment Paths at CIFIT 2026

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

USPS Honors 150 Years of the U.S. Coast Guard Academy

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Pizza: The Unlikely Symbol of Universal Togetherness

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Nocpix Unveils ACE 2 Thermal Riflescope Lineup

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

ARTiSTORY's Strategic Advance in Cultural IP Licensing

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

D-Wave Faces Legal Questions After CFO Exit and Losses

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Damp or Dry: The Battle for Healthy Air in Colorado

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...